Synaptic plasticity — the brain's ability to modify the connections between neurons to support learning — is one of the neural functions profoundly altered in Huntington's disease, with a direct ...

The successful gene therapy is AMT-130, developed by a company called UniQure. In a three-year trial of 29 participants with ...

On a video call in early September, Sarah Tabrizi first saw the data that she and other researchers studying Huntington’s ...

Researchers have found a new treatment for Huntington's disease, an inherited genetic brain disease that affects over 41,000 Americans, in breakthrough clinical trial that involved at least one ...

BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a ...

Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s ...

In 2025, nonprofits, charities and service organizations are navigating an economy in crisis and political machinations that often put their budgets and, sometimes, their very existence in peril. And ...

Dutch biotech uniQure has lost around half of its value after revealing that the FDA has indicated it is not prepared to review its gene therapy for Huntington's disease, which currently has no ...

Despite the best efforts of modern medicine, Huntington’s disease is a condition that still comes with a tragic prognosis. Primarily an inherited disease, its main symptoms concern degeneration of the ...

Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.

October meeting with the FDA confirm the agency doesn't see the data collected so far as enough to support an approval filing ...